CNBC
AstraZeneca stock dives 9% after heart drug trial misses target
Thursday, July 9, 2026
AstraZeneca's stock price fell 9 percent on the trading day following the announcement that its heart drug trial did not meet its primary endpoint. The company announced the trial results for the drug on a specified date. The decline reflected investor reaction to the missed efficacy target in the late-stage clinical trial. AstraZeneca has not disclosed specific details about alternative development pathways for the drug candidate.
Original reporting: https://www.cnbc.com/2026/07/09/astrazeneca-stock-trial-heart-drug-pharma.html